期刊文献+

胰岛素与口服降糖药对新诊断2型糖尿病患者β细胞功能的影响 被引量:6

Comparison of pancreatic islet functions between insulin and oral-hypoglycaemic-agents therapy in newly diagnosed type 2 diabetes mellitus
原文传递
导出
摘要 目的比较胰岛素(Ins)与口服降糖药(OHA)治疗对新诊断2型糖尿病(T2DM)患者胰岛β细胞功能的影响。方法 64例新诊断T2DM患者随机分为Ins组和OHA治疗组。定期检测PG、Ins、C-P水平及其他相关指标,用HOMA-β、HOMA-IR及ΔI_(30)/ΔG_(30)来评价胰岛功能变化。结果 (1)随访至6个月时,两组上述指标均无统计学差异(P均>0.05)。(2)随访至12个月时,与OHA组比,Ins组HOMA-β及ΔI_(30)/ΔG_(30)较治疗前显著上升(P<0.05)。两组HOMA-IR无统计学差异(P>0.05)。结论与OHA相比,早期Ins治疗能更好地保护β细胞功能。 Objective To investigate the effect of insulin (INS)and oral hypoglycaemic agents (OHA) on the function of islet β cells in newly diagnosed type 2 diabetes mellitus(T2DM). Methods Sixty four newly diagnosed T2DM patients were randomly assigned to insulin group(Ins group,n=30) and OHA group (n= 34). Blood was collected at regular intervals to determine plasma levels of glucose,insulin and C peptide and others. HOMA-β cells index. (HBCI), insulin resistence index (HOMA-IR), △I30/△G30 were calculated to assesse the islet β cell function. Results At the time of sixth month follow up, no significant differences in islet function were found between the two groups(P〉0.05). At the end of follow up (at twelfth month) ,the HBCI and △I30/△G30 increased significantly in Ins versus OHA group(P〈0. 05). The sex, age, BMI, systolic and diastolic blood pressure and HbA1 c showed no difference between two groups (P〉 0.05). Conclusions Compared with OHA, INS can protect islet β cell function of diabetes mellitus.
出处 《中国糖尿病杂志》 CAS CSCD 北大核心 2009年第5期348-349,共2页 Chinese Journal of Diabetes
关键词 糖尿病 口服降糖药 胰岛素 胰岛功能 Diabetes Oral hypoglycemic agents Insulin Islet function
  • 相关文献

参考文献8

二级参考文献7

共引文献367

同被引文献30

  • 1谢宗圆,何世宏,李海旺.用胰岛素泵强化治疗糖尿病的疗效观察[J].当代医药论丛,2014,12(2):114-115. 被引量:3
  • 2秦兴华.益气养阴活血化瘀法治疗2型糖尿病43例疗效观察[J].实用医学杂志,2005,21(1):88-89. 被引量:5
  • 3王妊,杨永年,编.糖尿病现代治疗学.北京:科学出版社,2007.16.
  • 4中华医学会糖尿病分会编.中国2型糖尿病防治指南(2010年版)北京:北京大学医学出版社.201124~25.
  • 5Dunn CJ, Plosker GL, Plosker GM, et al. Insulin glargine:an updated review of its use in the management of diabetes meUitus. Drugs,2003,63(16): 1743-1778.
  • 6Rosenstock J,Schwartz SL,Clark CM,et al,Basalinsulin therapy in thpe 2 diaketes: 28-week comparison of insulin g, largine(HOEg01) and NPH insulin. Diabetes Care,2001,24(4):631-636.
  • 7葛均波,徐永健.内科学[M].第8版.北京:人民卫生出版社,2013.259~265.
  • 8中华医学会糖尿病分会.中国2型糖尿病防治指南:2010年版[M]北京:北京大学医学出版社,201124-25.
  • 9Dunn C J,Plosker G L,Plosker G M. Insulin glargine:an updated review of its use in the management of diabetes mellitus[J].Drugs,2003,(16):1743-1778.
  • 10Dunn CJ,Plosker GL,Plosker GK,et al. Insulin glargine:an updated re- view of its use in the man-anement of diabetes mellitus[ J]. Drug,2008, 63(16) :1743 - 1778.

引证文献6

二级引证文献37

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部